Trials / Conditions / Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8

Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8

6 registered clinical trials studyying Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8.

Status	Trial	Sponsor	Phase
Withdrawn	Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers NCT05296005	Ohio State University Comprehensive Cancer Center	Phase 1
Active Not Recruiting	Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of NCT04929392	City of Hope Medical Center	Phase 2
Active Not Recruiting	Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advance NCT04391049	NRG Oncology	Phase 1
Completed	Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esopha NCT04097028	Roswell Park Cancer Institute	Phase 2
Active Not Recruiting	Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal NCT03784326	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer NCT03776487	M.D. Anderson Cancer Center	Phase 2